This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As he introduced Novartis’ meet-the-management event Thursday in London, CEO Vas Narasimhan hammered home Novartis’ status as a streamlined, “pure-play, innovative medicines” company and the succes | Novartis has adjusted its compound annual growth rate expectation from 5%-plus to 6%-plus through 2029.
AstraZeneca aims to open the facility in 2029. The Singapore manufacturing site will be AstraZeneca’s first facility capable of handling all steps of antibody drug conjugate production. The post AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs appeared first on MedCity News.
The agency previously gave the generic a tentative approval before some patents expire in 2029. . | The D.C. federal court denied Alvogen's bid to force the FDA to grant full approval to its proposed Xifaxan generic.
After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.
What you pay depends on your drug plan, whether your medication is subject to a deductible, the price tier or level it’s assigned by your plan, how much you have already spent on drugs during a given year, where you buy them, and — in the case of brand-name drugs — the whims of the pharma, PBM and insurance companies. Schumer (D-N.Y.)
According to some researchers and AI experts, there is a possibility that for people who are careful with their health and use new treatments, the rate of increase in life expectancy will reach 12 months per year, reaching the so-called “longevity escape velocity” between 2029 and 2035. appeared first on MaBiCo.
Boehringer Ingelheim’s recent M&A activity In November 2023, Boehringer announced that it planned to acquire the Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF). As a result, this approach could treat diseases addressing previously inaccessible drug targets, the company stated. $2
It is anticipated that operations will be ready to commence from 2029. He explained that an exciting development in the sector over the past several years is “the diversification of the biologics structures we are seeing in the pipeline of most major pharma and biotech companies. The post AstraZeneca announces $1.5b
According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging. The construction projects will be finalised from the end of 2025 through to 2029. Most of the investment will be focused on API capacity.
According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83 billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020.
The cell and gene therapy market in 2024 [Research from GlobalData predicts] that the top trend in the pharma industry in 2024 will be cell and gene therapy” With research from GlobalData predicting that the top trend in the pharma industry in 2024 will be cell and gene therapy, AstraZeneca’s new acquisition is supporting this outlook.
Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. billion in 2029 revenues.
Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. It has already licensed Chinese rights to the drug to Nuance Pharma for $40 million upfront plus up to $179 million in milestones and double-digit royalties.
In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. GlobalData anticipated it will launch in the US and 5EU (France, Germany, Italy, Spain, and the UK) markets during the forecast period, Sulayman Patel, MSci, Pharma Analyst at GlobalData noted. “As million in sales by 2032.
According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in 2029. Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023.
7,326,708) was challenged by Mylan Pharma, now Viatris, before the US Patent and Trademark Office (USPTO), which ruled in Merck’s favour last year. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029. The US patent (No.
According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47 billion in 2029. In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.
The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.
No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.
and 17.6%, respectively, according to J&J’s pharma unit Janssen. Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two hours of patient observation after administration.
According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.
This market dynamic will likely intensify both if more adalimumab biosimilars receive interchangeability designation and with increased pressure in the US Pharma market due to the Inflation Reduction Act of 2022. Currently, Boehringer Ingelheim’s Cyltezon is the only adalimumab biosimilar that has received interchangeability designation.
Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. Type 1 diabetes (T1D) is forecast to affect five million people in the eight major pharmaceutical markets, which are the US, France, Germany, Italy, Spain, UK, Japan, and Canada, by 2029.
According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. Tagrisso was approved for use as a first-line treatment for metastatic NSCLC with EGFR mutation in April 2018. GlobalData is the parent company of Pharmaceutical Technology.
In pharma sales, knowing your product is essential, but it’s not enough. billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.31% over the next five years[ source ]. What Are Soft Skills in Pharma Sales? Pharma sales here isn’t just about selling medicine – it’s about building long-term relationships.
billion by 2029, registering a CAGR of over 8% during the forecast period of 2022-2029. The product flow and dosing requirements of solids vary considerably from one industry to another, for example, product flow characteristics from foods to pharma. Recent analysis valued the market [i] at USD 8.5
According to consensus forecasts from GlobalData’s Pharma Intelligence Centre, Ocaliva is forecasted to have global sales of $1.08 billion in 2029. This results in bile buildup in the liver and can lead to scarring. The condition gradually worsens and can result in liver failure.
A second Trump administration would like face pushback if it abandoned or overturned the drug-pricing reforms of the Inflation Reduction Act, which includes numerous pieces that will prove popular with seniors, even as the industry faces price negotiations on top drugs, long an industry non-starter.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content